| Objective:In this study,30 patients with advanced solid tumor participated in autologous DC-CIK immunotherapy clinical trials. Statistics the datas of patients’ peripheral blood immune cell percentages and every aspects of quality of life rating scale before and after therapy. Illustrate the clinical efficacy and immune effect of DC-CIK cells therapy in patients with advanced solid tumors.Methods:30 cases of patients with advanced cancer confirmed by pathology and imaging were enrolled in Anhui Provincial Hospital from January 1,2014 to March 1, 2015. It includes 20 males and 10 females and their mean age was 63.27±11.27 years old. Diseases contain 10 patients of renal carcinoma(33.3%),10 cases of malignant melanoma(33.3%),2 cases of gastric adenocarcinoma in (6%),2 cases of non-small cell lung cancer(6%),2 cases of colorectal adenocarcinoma (6%),2 cases of ovarian serous adenocarcinoma(6%),1 cases of ureteral carcinoma(3%),1 cases of endometrial carcinoma(3%), many accompanied with metastatic lesions in different organs. Above patients all received two cycles of DC-CIK cell therapy. Isolated peripheral blood mononuclear cells by blood cell separator. Extracted lymphocytes by density gradient centrifugation and thoroughly washed. Suspended in eight 6-well culture plates with culture medium, placed in 37.5℃,5% CO2 incubator for 2h. Isolated the suspension cells and loose adherent cells. Suspension cells were cultured into CIK cells with BTN serum-free medium containing a certain percentage of CD3 monoclonal antibody, IFN-y, IL-2, autologous inactivated serum, inactivated fetal calf serum, gentamicin. Adherent cells were induced into DC cells with a certain proportion of GM-CSF, IL-4, TNF-a in order and cultured in 37.5℃,5%CO2 incubator. Regularly observed the cells’ growth and timely replenishment medium and cytokines. When cells became mature and bacteria, fungi, mycoplasma were tested negative and viable cells>95% using trypan blue staining, Collecting DC-CIK cells and washing the cells in 3 times with saline, then put them into saline containing inactivated serum from patients and intravenous reinfused in number of (1～3)×109. Using the flow cytometry to detect the ratio of peripheral blood immune cells and using EORTC-QLQ scores to assess the quality of life before and after patient reinfusion. Observed tumor markers change of patients and the adverse reactions of treatment.Results:After DC-CIK cells therapy, the clinical efficacy showed that 0 cases was assessed CR or PR,11 cases were assessed SD (36.67%),19 cases "were assessed PD(63.33%). ORR was 0.00%, DCR accounted for 36.67%. After treatment, the percentage of CD3+CD4+T cells, CD3-CD16+CD56+NK cells, CD3+CD56+cell in peripheral blood were increased compared with the previous, but the ratio of CD3+CD8 +T cell was decreased compared with the previous, so CD3+CD4+/CD3+CD8+ was increased. The ratio of CD3-CD19+cells, CD3+CD56" cells, CD8+ CD3-CD19+ B lymphocytes didn’t change. Analysis the statistical of patients’ QOL before and after treatment. It was obviously that the quality of life in roles/cognitive/social functioning, overall health status, nausea, vomiting, shortness of breath, insomnia, constipation, diarrhea were improved after treatment, the difference was statistically significant. Adverse reactions of DC-CIK treatment like fever, allergies, insomnia, etc. could be relived after symptomatic treatment.Conclusions:DC-CIK cells as auto-activated immune cells could improve the immune function and general situations of the patients with advanced solid tumors, which had a certain clinical effect and were safe for its little adverse reactions, so it could be used as one option for the patients who suffered the failures of chemotherapy and radiotherapy. |
PDF Full Text Request